Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idebenone in Prodromal Parkinson Disease
NCT04152655Phase 3Withdrawn
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Idebenone with Placebo (2 arms). Primary endpoint: Clinical diagnosis of parkinson disease at 24 months. Planned start Jan 2020; status: withdrawn.
02
Drugs
idebenone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04152655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04152655.